DNL 104, a Centrally Penetrant RIPK 1 Inhibitor, Inhibits RIP 1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers-Reference-Cited by-同舟云学术

DNL 104, a Centrally Penetrant RIPK 1 Inhibitor, Inhibits RIP 1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers

Published:2019-09-25 Issue:2 Volume:107 Page:406-414
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Grievink Hendrika W.¹^ORCID,Heuberger Jules A.A.C.¹^ORCID,Huang Fen²,Chaudhary Rinkal²,Birkhoff Willem A.J.¹^ORCID,Tonn George R.²,Mosesova Sofia²,Erickson Rebecca²,Moerland Matthijs¹,Haddick Patrick C.G.²,Scearce‐Levie Kimberly²,Ho Carole²,Groeneveld Geert Jan¹

Affiliation:

1. Centre for Human Drug Research Leiden The Netherlands

2. Denali Therapeutics South San Francisco California USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1615

Reference33 articles.

1. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha.

2. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis.